MeiraGTx Holdings PLC
MGTX8.470USD
+0.060+0.71%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
681.38MMarket Cap
LossP/E TTM
More Details of MeiraGTx Holdings PLC Company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
MeiraGTx Holdings PLC Info
Ticker SymbolMGTX
Company nameMeiraGTx Holdings PLC
IPO dateJun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
Number of employees381
Security typeOrdinary Share
Fiscal year-endJun 08
Address450 East 29Th Street
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10016
Phone16468607985
Websitehttps://meiragtx.com/
Ticker SymbolMGTX
IPO dateJun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
Company Executives of MeiraGTx Holdings PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-3.49%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
919.65K
-2.54%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-3.49%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
919.65K
-2.54%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 2
Updated: Thu, Oct 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
15.69%
Sanofi SA
15.16%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.50%
Prosight Capital
5.70%
Other
47.68%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
15.69%
Sanofi SA
15.16%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.50%
Prosight Capital
5.70%
Other
47.68%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.60%
Corporation
16.03%
Private Equity
15.69%
Venture Capital
8.26%
Investment Advisor
6.72%
Investment Advisor/Hedge Fund
5.41%
Individual Investor
4.18%
Research Firm
1.26%
Pension Fund
0.06%
Other
14.79%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
228
52.30M
65.02%
+2.51M
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
12.63M
15.69%
+45.00K
+0.36%
Jun 30, 2025
Sanofi SA
12.20M
15.16%
--
--
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.03M
7.5%
+400.00K
+7.10%
Jun 30, 2025
Prosight Capital
4.59M
5.7%
+895.88K
+24.27%
Jun 30, 2025
Rubric Capital Management LP
3.73M
4.63%
+1.95M
+109.78%
Jun 30, 2025
683 Capital Management LLC
2.69M
3.34%
+115.00K
+4.47%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.48M
3.09%
-243.04K
-8.91%
Jun 30, 2025
J. Goldman & Co., L.P.
2.04M
2.54%
+885.81K
+76.44%
Jun 30, 2025
Forbes (Alexandria)
1.36M
1.69%
-47.50K
-3.37%
Jul 08, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Micro-Cap ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs Innovate Equity ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
SPDR S&P International Small Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
